Daily SPAC Update – January 29, 2025

by | Jan 29, 2025

Finnovate (FNVTF) Delays Deal Vote to February. RACY and MAQC Set Extension Votes. JACS Separate Trading on Jan 30. Constellation (CSTAF) Extension Vote.

Boardroom Alpha SPAC Resources
– Full SPAC Listing
– SPAC SEC Filings
– Boardroom Alpha IPO & SPAC Intelligence Platform (7-Day Trial)

Daily SPAC Update

SPAC DEAL VOTES
FNVTF – FINNOVATE ACQUISITION CORP * Deal Vote Postponed

SPAC DEAL & EXTENSION VOTES SET
RACY – Relativity Acquisition Corp * EXTENSION VOTE SET: Feb 13, 2025 * trust $11.96
MAQC – Maquia Capital Acquisition Corp * EXTENSION VOTE SET: Jan 31, 2025 * trust $12.01

EXTENSION VOTES
CSTAF – CONSTELLATION ACQUISITION CORP I * Vote January 27, 2025 -> extend from January 29, 2025 to January 29, 2026

SEPARATE WARRANTS/RIGHTS
JACS on Jan 30

NEW SPAC IPOs
Jan 28: FGMC – Fg Merger Ii Corp. $80M IPO
Jan 27: DMAA – Drugs Made In America Acquisition Corp. $200M IPO

YESTERDAY’S TOP SPAC GAINERS
15.00% ~ $ 5.75 | RFAC – RF ACQUISITION CORP (Announced)
4.00% ~ $ 12.47 | WINV – WINVEST ACQUISITION CORP (Announced)
3.24% ~ $ 12.57 | IPXX – INFLECTION POINT ACQUISITION CORP II (Announced)
3.14% ~ $ 12.50 | TETE – TECHNOLOGY & TELECOMMUNICATION ACQUISITION CORP (Announced)
1.67% ~ $ 11.59 | FTII – FUTURETECH II ACQUISITION CORP (Announced)

YESTERDAY’S TOP SPAC LOSERS
-11.52% ~ $ 9.75 | WAVS – WESTERN ACQUISITION VENTURES CORP (Announced)
-7.56% ~ $ 11.00 | PLMJ – PLUM ACQUISITION CORP III (Pre-Deal)
-4.74% ~ $ 11.13 | DIST – DISTOKEN ACQUISITION CORP (Announced)
-2.58% ~ $ 11.69 | CSLM – CSLM ACQUISITION CORP (Announced)
-2.01% ~ $ 11.70 | PWUP – POWERUP ACQUISITION CORP (Announced)

LATEST SPAC IPO PERFORMANCE
Jan 28 | | FGMC – FG Merger II Corp.
Jan 27 |  | DMAA – Drugs Made In America Acquisition Corp.
Jan 21 | $ 10.02 | COLA – Columbus Acquisition Corp
Jan 16 | $ 10.02 | HVII – Hennessy Capital Investment Corp. VII
Jan 14 | $ 10.06 | RIBB – Ribbon Acquisition Corp.
Jan 14 | $ 10.04 | PLMK – Plum Acquisition Corp, IV
Jan 07 | $ 10.06 | CEPO – Cantor Equity Partners I, Inc.

 

Recent Analysis

Daily SPAC Update – May 1, 2026

Two SPAC IPOs launched today, raising a total of $500 million. CH4 Natural Solutions Acquisition Corp (MTNE) secured $300 million, while Quantum Leap Acquisition Corp (QLEP) raised $200 million. Today, 2 SPAC IPOs raised $500M, led by CH4 Natural Solutions (MTNE) at $300M. This follows a surge of activity at the end of April.

Daily SPAC Update – April 30, 2026

Today, six SPACs debuted, raising a total of $965 million. General Catalyst Global Resilience Merger Corp (GCGR) led the pack with $350 million, followed by RRE Ventures Acquisition Corp. (RREV) at $250 million. Month-to-date, SPAC IPOs total 16, bringing in $2.65 billion, compared to 11 IPOs last month that raised $1.72 billion.

Daily SPAC Update – April 29, 2026

Collective Acquisition Corp. II (CAII) launched its $220 million IPO today, targeting high-potential sectors like technology and healthcare. In executive moves, Roger Bendelac was appointed CEO of both Drugs Made in America Acquisition Corp (DMAA) and Drugs Made in America Acquisition II Corp (DMII), with Saleem Elmasri as CFO. Meanwhile, General Purpose Acquisition Corp (GPAC) saw a significant decline of 22.9%, closing at $9.96, while Aimei Health Technology Co Ltd (AFJK) gained 2.7% to $46.12.

Daily SPAC Update – April 28, 2026

SPAC IPOs Look Stalled Again as Irenic’s $220M IPO Only Makes it Seven. Miluna Acquisition + CADV.AI Deal. Prophyte Extension Vote to Add 12 More Months.

Subscribe to Boardroom Alpha Newsletters

Subscribe to Boardroom Alpha's research to receive the latest on governance, SPACs, and people.

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon. 

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.  

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by BA that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.  

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.